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Aim Sleep-disturbed breathing (SDB) is common in pre-capillary pulmonary hypertension (PH) and impairs daytime perform-
ance. In lack of proven effective treatments, we tested whether nocturnal oxygen therapy (NOT) or acetazolamide
improve exercise performance and quality of life in patients with pre-capillary PH and SDB.
Methods This was a randomized, placebo-controlled, double-blind, three period cross-over trial. Participants received NOT
(3 L/min), acetazolamide tablets (2 × 250 mg), and sham-NOT/placebo tablets each during 1 week with 1-week
washout between treatment periods. Twenty-three patients, 16 with pulmonary arterial PH, 7 with chronic thrombo-
embolic PH, and with SDB defined as mean nocturnal oxygen saturation ,90% or oxygen saturation dips .10 h21
with daytimePaO2≥7.3 kPaparticipated. Assessments at theend of the treatmentperiods includeda6 minwalkdistance
(MWD), SF-36 quality of life, polysomnography, and echocardiography.
Results Medians (quartiles) of the 6 MWD after NOT, acetazolamide, and placebo were 480 m (390;528), 440 m (368;468), and
454 m (367;510), respectively, mean differences: NOT vs. placebo +25 m (95% CI 3–46, P ¼ 0.027), acetazolamide vs.
placebo 29 m (234–17, P ¼ 0.223), and NOT vs. acetazolamide +33 (12–45, P, 0.001). SF-36 quality of life was
similar with all treatments. Nocturnal oxygen saturation significantly improved with both NOT and acetazolamide. Right
ventricular fractional areachangewas greateron NOT compared with placebo (P ¼ 0.042) and acetazolamide (P ¼ 0.027).
Conclusions In patients with pre-capillary PH and SDB on optimized pharmacological therapy, NOT improved the 6 MWD compared
with placebo already after 1 week along with improvements in SDB and haemodynamics.
ClinicalTrials.gov NTC01427192.
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Introduction
Pre-capillary pulmonary hypertension (PH) is a severe condition
leading to progressive right heart failure with impaired quality of
life, reduced exercise capacity and pre-mature death.1 In the
absence of relevant lung diseases, the two major groups are pulmon-
ary arterial hypertension (PAH), including idiopathic and associated
forms, and chronic thromboembolic pulmonary hypertension
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(CTEPH).1 Treatment consists in prescription of drugs and, in
selected cases, pulmonary endarterectomy or lung transplantation.2
Sleep reduces respiratory drive, upper airway stability and may there-
fore lead to ventilatory instability with apnoea/hypopnoea associated
with intermittent hypoxaemia, or sustained hypoxaemia due to a
relative hypoventilation.3 Hypoxaemia induces pulmonary vasocon-
striction and may aggravate PH by its effects on pulmonary vascular
smooth muscle and endothelial cells.4 Sleep-disturbed breathing
(SDB) including sleep apnoea and nocturnal hypoxaemia affect
more than two-thirds of patients with right heart failure due to
PH.5 –7 As in left heart failure, PH with right ventricular dysfunction
might promote SDB by a delayed and enhanced chemoreflex feed-
back, and by an increased plant gain resulting in unstable feedback
control.8 Sleep-disturbed breathing in patients with PH is clinically
relevant since it may further impair daytime performance, exercise
capacity, pulmonary haemodynamics, and quality of life.5 Sleep-
disturbed breathing may also adversely affect prognosis as reported
in patients with left heart failure.5
The indications, types and benefits of different potential treat-
ments for SDB in pre-capillary PH are currently not known. Extrapo-
lating from left heart failure, nocturnal oxygen therapy (NOT),
acetazolamide, or non-invasive positive pressure ventilation via a
mask may be effective.9,10 In the present randomized, placebo-
controlled trial, we tested the hypothesis that treatment with NOT
or acetazolamide, respectively, during 1 week ameliorates exercise
capacity, quality of life and SDB in patients with pre-capillary PH.
Methods
Design and setting
This is a randomized, double-blind, sham and placebo-controlled three-
period cross-over trial in patients with PH and SDB. The study compared
effects of (i) nocturnal supplemental oxygen by nasal cannula with a flow
rate of 3 l/min (NOT) and placebo tablets, (ii) acetazolamide tablets and
sham-NOT (room air by nasal cannula with a flow rate of 3 l/min), with
(iii) sham-NOT and placebo tablets (Figure 1). In the following, these
three treatment combinations are termed NOT, acetazolamide, and
placebo, respectively. Each treatment was applied for 1 week in the
patients’ home. Assessments took place in the lastnightof each treatment
period and in the following morning at the Pulmonary Clinic, University
Hospital of Zurich. During washout periods of 1 week, patients did not
receive any study treatment. The trial was performed from December
2010 to August 2012. The study was approved by the local ethics
review board. The trial is registered at clinicalTrials.gov: NTC-01427192.
Patients
Consecutive patients aged 20–80 years, either gender, diagnosed with
PAH or inoperable CTEPH (WHO group I or IV) at our tertiary care out-
patient clinic were eligible for enrolment upon written informed consent.
All patients were diagnosed according to current guidelines and had
undergone right heart catheterization at the time of initial evaluation.1
Patients were considered for inclusion if they were in a stable condition
on the same medication for .4 weeks. Eligible patients had no severe
daytime hypoxaemia (PaO2 ≥7.3 kPa) but suffered from SDB defined
as either a mean nocturnal oxygen saturation (SpO2) ,90% or an
oxygen desaturation index (ODI,.3% dips).10 dips/h during an ambu-
latory nocturnal pulse oximetry. Patients with PaO2 ,7.3 kPa during
daytime, predominantly obstructive sleep apnoea, more than mild lung
disease (forced expiratory volume in 1 s ≤60%) or concomitant left
ventricular disease were excluded.
Interventions, randomization, and blinding
NOT (or sham-NOT corresponding to room air) was delivered via a nasal
cannula at a flow rate of 3 L/min by an oxygen concentrator (Respironics
EverFloTM, Zofingen, Switzerland). The sham-concentrators were pre-
pared by modifying the same type of concentrators to provide room
air instead of oxygen at identical flow rates. Patients were instructed in
the use of the oxygen (or sham) concentrators by a blinded investigator
who delivered the device to the patient’s home and collected it at the
end of each treatment phase.
A set of the study medication was given to the patient at the beginning of
each study period. Acetazolamide (Diamox, Vifor, Fribourg, Switzerland)
was administered at a dose of 2× 250 mg/day with breakfast and dinner,
respectively. Similarly, capsules containing acetazolamide and placebo
were prepared by the Cantonal pharmacy of Zurich and packed in contain-
ers labelled with a code that was broken only after data analysis.
Allocation to one of the six possible study sequences was performed
by an independent pharmacist by a computer generated randomization
list assuring a balanced block design. Patients and investigators participat-
ing in evaluation of outcomes were blinded to the treatment (double-
blind design).
Assessments
Assessments were performed on the last day/night of each 1-week treat-
ment period (Figure 1).
A6 minwalkdistance (MWD)wasassessedat10–11a.m. after thecom-
pletion of all other assessments by experienced nurses blinded to the treat-
ment.11 Qualityof lifewas assessed by the1-week-recall formSF-36and the
Minnesota living with heart failure questionnaire.12,13 Sleepiness was
assessed by the Epworth sleepiness scale.14 Medical history, NYHA/
WHO functional class, and physical examination were assessed.
Patients were examined by echocardiography at 9 a.m. after the sleep
study. Cardiac morphological and functional parameters were assessed
by standard two-dimensional Doppler echocardiography (Philips iE33;
Philips, Zofingen, Switzerland) by an experienced cardiologist blinded to
the patients’ clinical data and treatment (Felix C. Tanner). The dimensions
of right ventricle and right atrium, right ventricular fractional area change,
and tricuspid annular plain systolic excursion were determined.15,16
Maximal systolic flow velocity of the tricuspid regurgitation jet was mea-
sured by continuous wave Doppler and the maximal systolic pressure gra-
dient between right ventricle and right atrium calculated using the
simplified Bernoulli equation; right atrial pressure was estimated by the di-
mension and respiratory variability of the inferior cava vein.15,16
A radial artery blood samplewasobtained while the patient was resting
quietly breathing room air. Analysis was performed immediately (ABL
90Flex-blood gas analyser, Radiometer, Switzerland). NT-pro brain
natriuretic peptide was analysed in a venous blood sample by immuno-
assay (Roche Modular Systems, Rotkreuz, Switzerland).
Polysomnography was performed from 10 p.m. to 6:30 a.m. in the
sleep laboratory according to standard methods in the last night of
each treatment period.5,17,18 Measurements included electroencephal-
ography, electrooculography, electromyography of submental and
tibial muscles, nasal pressure to assess airflow, oral thermistor, calibrated
respiratory inductance plethysmography, pulse oximetry, transcutane-
ous carbon dioxide tension, electrocardiogram, body position, and
audio-visual recordings (Alice5, Philips, Respironics, USA).5 Sleep
studies were analysed as described previously.5 An apnoea/hypopnoea
was defined as a reduction of the breathing amplitude to ,50% in com-
parison to the preceding baseline lasting for ≥10 s. Central apnoea/
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hypopnoeas were differentiated from obstructive events by the absence
of asynchronous and paradoxical rib cage-abdominal excursions and by
diaphragmatic surface EMG. The apnoea/hypopnoea index (AHI) was
computed as the number of events per hour. Periodic breathing was
scored when at least three continuous cycles of waxing and waning
tidal volumes were present with periods of hyperventilation separated
by central apnoeas or hypopnoeas.
Psychomotor vigilance tests (PVTs) were performed in a quiet room
between 7 and 8 a.m. The reaction time to a light signal appearing at
irregular intervals was measured during a 15 min session.19
Figure 1 Patient flow. PaO2, partial pressure of arterial oxygen; AZM, treatment with acetazolamide tablets 250 mg twice a day; NOT, nocturnal
oxygen therapy via a nasal cannula at a flow rate of 3 L/min. Sham-NOT, room air at a flow rate of 3 L/min. Placebo, tablets twice a day.
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Outcomes
Primary outcomes were the 6MWD and the SF-36 physical component
summary. Additional outcomes were the SF-36 and Minnesota living with
heart failure quality-of-life domains, WHO/NYHA functional class, echo-
cardiographic assessments of the tricuspid pressure gradient, the tricus-
pid annular plane systolic excursion and right ventricular fractional area
change, arterial blood gases, venous N-terminal brain natriuretic
peptide, and variables derived from sleep studies such as nocturnal
oxygen saturation, sleep apnoea events, sleep structure, and PVT reac-
tion time.
Data analysis and statistics
We calculated that a sample size of 22 patients was required including a
10% drop-out rate to detect minimally important differences in primary
outcomes (35 m for the 6 min walk and 9 points for the SF-36 physical
scale) with 80% power and a two-sided significance level of ,0.05.20–22
Results are reported as number (%), medians (quartiles), and mean
differences with 95% CI. All analyses were performed on an intention-
to-treat basis. Missing data were replaced by the corresponding value on
the alternative intervention or the group mean conservatively assuming
no effect of the respective treatment.23 Outcomes were analysed by
analysis of variance with Bonferroni correction and Wilcoxon matched
pairs tests. Repeated measures analysis of variance was performed to
assess potential effects of exposure sequence and time effects. Statistical
significance was assumed at P, 0.05.
Results
Of 72 PH-patients screened, 23 met the inclusion criteria and were
randomized (Figure 1). Twenty-eight patients could not be included,
although they had sleep-related hypoxaemia, because they could not
undergo assessment of the main outcome, the 6MWT (n ¼ 9), had
daytime hypoxaemia (PaO2 ,7.3 kPa) (n ¼ 4), or did not consent.
Baseline characteristics of these 28 patients were similar to the 23
patients participating in the trial (Supplementary material online,
Table S1). Patients were predominantly females with idiopathic
PAH or inoperable CTEPH. According to entry criteria, patients
were in stable condition, WHO/NYHA functional classes II to IV,
on optimized single or multiple PH target therapies (Table 1). All par-
ticipants completed the study. The 6MWD could not be obtained in
one patient afterNOTand acetazolamidewhowas unable towalk for
6 min due to arthritic hip pain, another patient did not fill the SF-36
questionnaire during the study period on acetazolamide.
Primary outcomes
Exercise capacity and quality of life
After 1 week of NOT, the 6MWD was significantly greater than the
6MWD on placebo, respectively, acetazolamide (Table 2, Figure 2).
Acetazolamide had no significant effect on the 6MWD compared
with placebo. Quality of life assessed by the 1 week-recall form of
SF-36 was similar on all treatments (Table 2 and Supplementary ma-
terial online, Table S2).
Additional outcomes
Functional class, disease-specific quality of life and
sleepiness
WHO/NYHA functional classes I/II/III/IV were found in 0/7/12/4
patients after placebo, 1/11/8/3 after NOT and 0/7/11/5 after
acetazolamide (Figure 3). Thus, five more patients were in the
target WHO/NYHA classes I/II with NOT compared with placebo
and acetazolamide (absolute risk reduction 0.21, number needed
to treat 5). The Minnesota living with heart failure questionnaire
and the Epworth sleepiness scale revealed no difference between
treatments (Table 2 and Supplementary material online, Table S1).
Echocardiography
We found a significantly higher right ventricular fractional area
change with NOT compared with placebo (Table 2). Tricuspid
annular plane systolic excursion and the tricuspid valve systolic pres-
sure gradient were comparable in all groups.
Sleep and vigilance studies
Nocturnal oxygen therapy and acetazolamide both significantly
improved the total and central AHI, the percentage of the night
spent with periodic breathing and the mean nocturnal oxygen satur-
ation comparedwith sham-NOT/placebo (Table2). In addition, NOT
increased the amount of deep sleep (NREM stages III and IV) which
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Table 1 Baseline characteristics
Characteristic Number (%) or
median (quartiles)
Number of participants (females) 23 (15)
Age (year) 66 (56; 71)
BMI (kg/m2) 26.6 (25.2; 29.3)
NYHA class (II, III, IV) 6 (26), 14 (61), 3 (13)
Classification, n (%)
Pulmonary arterial hypertension 16 (70)
Idiopathic 13 (57)
Connective tissue disease 1 (4)
Congenital heart disease 1 (4)
Porto-pulmonary 1 (4)
Chronic thromboembolic PH 7 (30)
Meanpulmonaryarterial pressure (mmHg)a 44 (32;52)
Pulmonary capillary occlusion pressure
(mmHg)a
11 (9;13)
Pulmonary vascular resistance (dyn s m25)a 505 (373;742)
6MWD (m) 448 (375;501)
Daytime oxygen saturation (%) 93 (91;95)
Mean nocturnal oxygen saturation (%) 87 (86;89)
Oxygen desaturation index (.3%) (1/h) 14 (4;24)
PH-specific medication
PDE-5 inhibitor 11 (48)
Endothelin receptor antagonist 18 (78)
Prostanoid therapy 4 (17)
Patient on combination therapy
Two-drug combination 6 (26)
Three-drug combination 4 (17)
Data obtained during screening or aobtained during last right heart catheterization.
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Table 2 Effects of nocturnal oxygen and acetazolamide treatment
Placebo/
sham-O2
NOT Acetazolamide DNOT2
placebo
(95% CI)
P
Wilcoxon
Dacetazolamide2
placebo
(95% CI)
P
Wilcoxon
DNOT2
aceta-zolamide
(95% CI)
P
Wilcoxon
P
ANOVA
(overall)
Exercise capacity
6MWD 454 (366, 510) 480 (390, 530) 440 (366, 472) 25 (3 to 46) 0.027 29 (234 to 17) 0.223 33 (21 to 46) ,0.001 ,0.001
Quality of life
SF-36 physical
component summary
38 (34, 44) 41 (33, 47) 38 (33, 49) 2 (21 to 4) 0.140 21 (24 to 2) 0.974 3 (21 to 7) 0.263 0.293
SF-36 mental component
summary
58 (53, 62) 58 (53, 62) 59 (47, 62) 1 (23 to 4) 0.695 24 (27 to 20) 0.052 4 (21 to 9) 0.211 0.153
WHO/NYHA functional
class
3 (2;3) 2 (2;3) 3 (2;3) 0 (21 to 0) 0.052 0 (0 to 0) 0.705 0 (21 to 0) 0.021 0.037
MLHF general 17.0 (13.0, 37) 20.0 (9.5, 47.0) 17.0 (7.0, 30.0) 1 (23 to 5) 0.438 22 (26 to 2) 0.306 4 (21. to 8) 0.163 0.444
Echocardiography
Right ventricular
fractional area
change (%)
32 (19; 35) 32 (21; 38) 30 (18; 35) 2 (0 to 4) 0.042 0 (22 to 2) 0.984 2.0 (0.1 to 4.0) 0.027 0.022
Tricuspid pressure
gradient (mmHg)
62 (43; 86) 56 (44; 71) 53 (47; 75) 22.5 (27 to 2) 0.420 24 (28 to 0) 0.068 2 (22 to 5) 0.449 0.412
Tricuspid annular plane
systolic excursion
(mm)
21.0 (18.0; 23.0) 20.5 (18.0; 23.0) 20.5 (18.0; 23.0) 0.2 (21 to 1) 0.653 0 (21 to 1) 0.796 0.2 (21.2 to 1.7) 0.925 0.905
Sleep studies and vigilance
Mean nocturnal arterial
oxygen saturation (%)
86 (84, 89) 92 (91, 94) 90 (88, 92) 6 (4 to 7) ,0.001 3 (2 to 4) ,0.001 2 (1 to 4) 0.001 ,0.001
Oxygen desaturation
index (ODI)
7 (0, 16) 0 (0, 3) 2 (1, 13) 211 (220 to 22) 0.002 24 (210 to 1) 0.105 27 (213 to 0) 0.021 0.006
Total AHI (1/h) 18 (6, 40) 9 (6, 24) 7 (3, 27) 211 (217 to 23) 0.002 210 (218 to 21) 0.004 0 (27 to 6) 0.976 ,0.001
Periodic breathing
(% total sleep time)
8 (2, 22) 1.8 (0, 7) 2.6 (0, 14) 212 (220 to 24) ,0.001 28 (215 to 21) 0.030 24 (211 to 3) 0.309 ,0.001
Mean reciprocal reaction
time (response
speed, 1/s)
3.5 (3.2, 3.9) 3.7 (3.5, 3.9) 3.3 (3.1, 3.49) 0.2 (20.2 to 0.5) 0.543 20.2 (20.5 to 20.0) 0.004 0.4 (0.2 to 0.7) ,0.001 ,0.001
Blood analysis
Arterial pH 7.43 (7.41, 7.45) 7.43 (7.40, 7.45) 7.35 (7.33, 7.37) 0 (0 to 0) 0.073 20.1 (20.1 to 20.1) ,0.001 0.1 (0.06 to 0.09) ,0.001 ,0.001
PaO2 (kPa) 7.8 (6.9, 8.5) 7.5 (6.9, 8.2) 8.7 (8.1, 9.5) 20.1 (20.9 to 0.7) 0.465 0.9 (0.3 to 1.5) 0.004 21.0 (21.6 to 20.3) 0.008 ,0.001
PaCO2 (kPa) 4.4 (4.1, 4.9) 4.6 (4.3, 5.1) 3.9 (3.5, 4.2) 0.2 (0.1 to 0.4) 0.010 20.6 (20.7 to 20.5) ,0.001 0.8 (0.7 to 0.9) ,0.001 ,0.001
Continued
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was not observed with acetazolamide (Supplementary material
online, Table S3). Psychomotor vigilance test reaction speed was
reduced on acetazolamide compared with the other treatments.
Additional results of sleep studies and vigilance tests are shown
online (Supplementary material online, Table S3).
Arterial and venous blood analyses
The arterial pH was significantly reduced with acetazolamide com-
pared with placebo (P, 0.001) along with an increased PaO2,
decreased PaCO2, and bicarbonate (Table 2). NT-pro-BNP was
lower after acetazolamide compared with placebo (P ¼ 0.007).
Tolerability,drug accountability,preferences, and influence
of treatment sequences
Nocturnal oxygen therapy and acetazolamide were subjectively well
tolerated with no major adverse events reported by the patients.
Prickling sensation in the fingers, dry nose, and fatigue were reported
by 1/3/0 after sham-NOT/placebo, 0/3/0 after NOT and 3/4/3 after
acetazolamide. Drug accountability after each 1 week treatment
period indicated that all patients took the tablets as prescribed.
After NOT, placebo, and acetazolamide 19, 19, and 20/23 patients
(83, 83, and 87%) reported that they would use NOT if it would
help and only one patient declared not to use NOT regardless of
any benefit. However, 20, 20, and 21/23 patients (87 resp. 91%)
would prefer tablets to NOT therapy if it would help equally.
Three, 1, and 0 patients each had no preferences on NOT, placebo,
and acetazolamide each. To evaluate the effect of treatment se-
quence on the 6MWD analysis of variance was performed with treat-
ment sequence and type of treatment as independent variables. The
results confirmed a significant effect of treatment (P ¼ 0.004) but
did not suggest any effect of the treatment sequence (P ¼ 0.157,
P interaction ¼ 0.364).
An exploratory subgroup analysis revealed that patients with PAH
(n ¼ 16) tended to improved their 6MWD during NOT compared
with placebo (481 (406;557) vs. 460 (386;533) m, P ¼ 0.076) and sig-
nificantly improved it compared with acetazolamide (440 (372;507)
m, P ¼ 0.004). The seven patients with CTEPH tended to improve
Figure 2 Change in 6 min walk distance after nocturnal oxygen
therapy and acetazolamide. The mean differences with the corre-
sponding 95% confidence interval in the 6 min walk distance after
1 week acetazolamide tablets, respectively, nocturnal oxygen
therapy compared with placebo/sham-oxygen are shown.
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their 6MWD during NOT (444 (356;532) vs. 426 (319;533) m,
P ¼ 0.173 and significantly improved it vs. acetazolamide (432
(350;314), P ¼ 0.028). The differences in quality-of-life scales were
notdifferent for thepulmonaryarterial andCTEPH(datanot shown).
Discussion
This randomized, sham/placebo-controlled, double-blind trial in
patients with PAH and CTEPH suffering from SDB demonstrates
that 1 week of NOT improved the 6MWD compared with placebo
andacetazolamide, respectively. The favourable effectof NOTonex-
ercise performance was associated with improvements in right
ventricular fractional area change, in sleep-related breathing dis-
turbances and with a reduced WHO/NYHA functional class in 8 of
23 patients (35%). In contrast, treatment with acetazolamide did
not change exercise performance, functional class and pulmonary
haemodynamics, although SDB was improved to a similar degree as
with NOT.
Sleep inducesprofoundphysiological alterations to the respiratory
system even in healthy subjects.24 Possible underlying mechanisms
are mismatched ventilation-perfusion, reduced functional residual
capacity due to recumbent position and reduced respiratory drive.
Pre-existing cardiopulmonary diseases potentiate these mechanisms
and worsen SDB.25 Thus, periodic breathing and nocturnal hypox-
aemia are highly prevalent in patients with left heart failure, lung dis-
eases, and pre-capillary PH5– 7,26,27 and SDB is underestimated by
daytime office assessments.6 In analogy to patients with left heart
failure,9,10 we tested whether NOT or acetazolamide would
improve SDB and herewith exercise performance, symptoms,
quality of life and pulmonary haemodynamics in PH. Both, NOT
and acetazolamide, improved SDB in PH, but only NOT improved
the 6MWD in comparison to placebo (by a mean of 25). This im-
provement is remarkable for several reasons: NOT improved the
6MWD even in patients on optimized pharmacological PH target
therapy (44% of the patients were even on double or triple PH
target therapy). Several randomized-controlled studies investigating
the effect of target medication for pre-capillary PH over 12–16
weeks used the 6MWD as endpoint. The gain in 6MWD in these
studies was mostly comparable with our study.28,29 In contrast to
our study, a significant increase in the 6MWD was often not achieved
in randomized-controlled trials byadding drugs to patients alreadyon
PH target therapy (combination therapy).30– 33 Moreover, in the
present trial, NOT was given for a short period of 1 week only and
the 6MWD was performed 10–11 a.m., 4 h after cessation of
NOT. In analogy to our study, a 1 week therapy with NOT-improved
SDB and exercise capacity in patients with left heart failure.34 Thus,
the improvement on NOT in patients with left- and right heart
failure and SDB seems to be comparable. The fact that acetazolamide
did not increase the 6MWD, although it improved sleep-related
breathing disturbances to a similar degree as NOT suggests that
the two treatments may act via different physiologic pathways as
will be further discussed below.
Figure 3 Distribution of WHO/NYHA functional classes after each treatment period. The percentage of patients in WHO/NYHA functional
classes’ I– IV is shown as assessed after each 1 week treatment period: nocturnal oxygen therapy, acetazolamide, and sham-nocturnal oxygen
therapy/placebo, respectively.
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In our short-term study, we did not find a significant difference in
quality of life assessed by the 1-week-recall form of the SF-36 physical
component score, SF-36 domain scores or quality of life by the Min-
nesota living with heart failure questionnaire, a disease-specific in-
strument. Potentially, the duration of our study was too short to
consistently ameliorate quality of life. Nevertheless, NOT had a fa-
vourable effect on symptoms, as one-third of patients improved
their WHO/NYHA functional class on NOT (Figure 3) resulting in
additional five patients reaching the treatment goal of being in
Class I/II after 1 week of NOT (totally 12 patients compared with 7
on sham-NOT or acetazolamide). Thus, five patients would need
treatment for 1 week in order to have one patient in the target
WHO/NYHA class II. These results underscore that NOT, albeit
given for a short time only, has the potential to improve patient
centred outcomes.
Right heart function is a main determinant of disease severity and
outcome in pre-capillary PH.35–37 NOT therapy was associated with
a significant improvement in right ventricular function reflected in a
higher fractional area change. Supplemental oxygen has been shown
to improve right ventricular function in patients with chronic ob-
structive pulmonary disease in association with a decreased pulmon-
ary vascular resistance.38,39 However, our study failed to show an
improvement of the tricuspid valve systolic pressure gradient, as sur-
rogate of pulmonary artery pressure. Possibly, the treatment period
of 1 week was too short to improve several markers of right ventricu-
lar function and our study may have been underpowered to detect
minor changes in some of the secondary outcomes. Nevertheless,
the observed increase in right ventricular fractional area change
points towards a right heart functional improvement by NOT and
warrants further study.
We found that acetazolamide and NOTwerehighlyeffective in im-
proving SDB with a significant decrease in central sleep apnoea, re-
duction in periodic breathing, oxygen desaturation index, and a
marked improvement in nocturnal SpO2. This corresponds with
improvements in SDB previously described for patients with left
heart failure on these therapies or the improvement of periodic
breathing in mountaineers or patients with obstructive sleep
apnoea travelling to altitude.9,34,40–42 Acetazolamide has been
shown to improve hypoxic pulmonary vasoconstriction in dogs,43
to ameliorate pulmonary haemodynamic in hypoxia-exposed rats
and its prophylactic effect for high-altitude-associated illness is well
known.44 In contrast to NOT, acetazolamide did not ameliorate ex-
ercise capacityor function in our study. This might be partlyexplained
by the introduction of metabolic acidosis by acetazolamide, which
had to be compensated by increased ventilation in PH-patients
which already tend to hyperventilate. Arterial blood gases of our
patients on acetazolamide revealed an increased partial pressure of
oxygen along with a decreased partial pressure of carbon dioxide, bi-
carbonate, and pH. Acidosis may also impair pulmonary haemo-
dynamics by an increased pulmonary vascular constriction. On the
otherhand, thediuretic effectof acetazolamide mighthavedecreased
right atrial pressure, right ventricular preload and thereby might have
lowered the tricuspid valve systolic gradient, a tendency which was
found in our cohort (Table 2, P ¼ 0.068). Despite higher partial pres-
sures of oxygen due to hyperventilation, acetazolamide is associated
with a less efficient breathing and respiratory muscle fatigue,45,46
which might further explain the impaired exercise performance in
our PH-cohort during acetazolamide therapy. However, it may
well be that acetazolamide given only before sleep and not in the
morning, would have improved exercise capacity during the day as
well as improved SDB.
Although we could not include several screened patients with noc-
turnal hypoxaemia into the current trial because they could not
undergo assessment of the main outcome, the 6MWT, and for
other reasons (Figure 1) we feel that the proportion of PH patients
who might benefit from NOT is relatively large since 51 of 72 con-
secutive patients with pre-capillary PH, i.e. 79% revealed nocturnal
hypoxaemia that might respond favourably to NOT.
Our study has important clinical implications: patients with pre-
capillary PH who suffer from periodic breathing and/or nocturnal
hypoxaemia, may benefit from NOT even if daytime arterial oxygen-
ation is relatively well preserved. Compared with pharmacological
pH therapies, NOT is an inexpensive therapy without serious side
effects.
In summary, this randomized, placebo-controlled, double-blind
trial demonstrates for the first time that treatment with NOT not
only ameliorates nocturnal oxygenation and periodic breathing in
patients with PAH or inoperable CTEPH and SDB but also improves
exercise capacity, functional class and potentially right ventricular
function already within 1 week. As NOT is inexpensive and save,
SDB should be diagnosed and NOT considered in these patients.
The long-term effect of NOT in PH-patients with SDB and preserved
daytime oxygenation should be studied in future randomized trials.
Supplementary material
Supplementary material is available at European Heart Journal online.
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